Does Rallies show Form 4 insider transactions for SEPN?

Yes. Rallies tracks SEPN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is SEPN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SEPN. It does not provide personalized investment advice.

SEPN (Septerna, Inc. Common Stock) Stock Analysis - Insider Trades

Septerna, Inc. Common Stock (SEPN) is a publicly traded Healthcare sector company. As of May 21, 2026, SEPN trades at $27.99 with a market cap of $1.19B and a P/E ratio of -33.78. SEPN moved +5.70% today. Year to date, SEPN is +4.55%; over the trailing twelve months it is +197.35%. Its 52-week range spans $4.17 to $32.63. Analyst consensus is strong buy with an average price target of $42.25. Rallies surfaces SEPN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading SEPN stock inside the company?

Recent SEPN insider activity includes Bhatt Elizabeth sold 2.57K, Bhatt Elizabeth sold 1.10K, Bhatt Elizabeth sold 326, Shaikhly Samira sold 4.09K, and Shaikhly Samira sold 66.36K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

SEPN Key Metrics

Key financial metrics for SEPN
Metric	Value
Price	$27.99
Market Cap	$1.19B
P/E Ratio	-33.78
EPS	$-0.81
Dividend Yield	0.00%
52-Week High	$32.63
52-Week Low	$4.17
Volume	24
Avg Volume	0
Revenue (TTM)	$72.25M
Net Income	$-36.04M
Gross Margin	0.00%

Recent SEPN Insider Trades

Bhatt Elizabeth sold 2.57K (~$61.12K) on Apr 15, 2026.
Bhatt Elizabeth sold 1.10K (~$27.79K) on Apr 15, 2026.
Bhatt Elizabeth sold 326 (~$8.43K) on Apr 15, 2026.
Shaikhly Samira sold 4.09K (~$112.50K) on Mar 2, 2026.
Shaikhly Samira sold 66.36K (~$1.87M) on Mar 2, 2026.

Latest SEPN News

Septerna posts $522M cash, Q1 revenue $26.5M; advances SEP-631, launches SEP-479 trial — May 11, 2026
Septerna Posts $24.12M Q4 Revenue, Reports $0.24 Loss per Share — Mar 9, 2026
Septerna’s SEP-631 Shows Complete Wheal Inhibition at 10 mg Daily, Eyes Phase 2b — Mar 1, 2026
Septerna to Present Phase 1 SEP-631 Data on March 1 at AAAAI Meeting — Feb 10, 2026

SEPN Analyst Consensus

6 analysts cover SEPN: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $42.25.

Common questions about SEPN

Who is trading SEPN stock inside the company?: Recent SEPN insider activity includes Bhatt Elizabeth sold 2.57K, Bhatt Elizabeth sold 1.10K, Bhatt Elizabeth sold 326, Shaikhly Samira sold 4.09K, and Shaikhly Samira sold 66.36K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for SEPN?: Yes. Rallies tracks SEPN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is SEPN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SEPN. It does not provide personalized investment advice.